TP53 and malignant colon neoplasm: Furthermore, experiments of isogenic HCT-116 colon cancer cell lines with different mutant or wild-type p53 variants demonstrated either p53-dependent or independent antitumor responses depending on the type of HDACi treatment [284,285].